Journal of Psychopharmacology
April 1, 2025
Monika Maciag, Olga Doszyn, Artur Wnorowski et al.
4 citations
Mental disorders, including anxiety and depression, impact nearly 1 billion people worldwide. Recent research has highlighted the potential of certain amphetamine compounds in the therapy of psychiatric disorders, with 3,4-methylenedioxymethamphetamine (MDMA) emerging as a promising candidate. This study investigates the effects of MDMA on anxiety and social behaviours using 3-week-old...
Frontiers in Behavioral Neuroscience
August 2, 2018
Barbara Budzynska, Artur Wnorowski, Katarzyna Kaszubska et al.
9 citations
3,4-Methylenedioxy-methylamphetamine (MDMA), a synthetic substance commonly known as ecstasy, is a worldwide recreational drug of abuse. As MDMA and nicotine activate the same neuronal pathways, we examined the influence of co-administration of nicotine (0.05 mg/kg) and MDMA (1 mg/kg) on cognitive processes, nicotine-induced behavioral sensitization and on processes linked with oxidative stress...
Pharmacological Reports
April 2017
Barbara Budzynska, Agnieszka Michalak, Małgorzata Frankowska et al.
Abuse of more than one psychoactive drug is becoming a global problem. Our experiments were designed to examine the effects of a concomitant administration of 3,4-methylenedioxy-methamphetamine (MDMA) and mephedrone on depression- and anxiety-like behaviors and cognitive processes in Swiss mice. In order to investigate the drug interactions the forced swimming test (FST) - an animal model of...
Molecular Neurobiology
December 6, 2016
Marta Kruk-Słomka, A. Dzik, Barbara Budzynska et al.
The endocannabinoid system via cannabinoid (CB: CB1 and CB2) receptors and their endogenous ligands is directly and indirectly involved in many physiological functions, especially in memory and learning processes. Extensive studies reported that this system strictly modulates cognition-related processes evaluated in various animal models. However, the effects of cannabinoids on the cognition...